UNSPSC 51101668: Miltefosine

This classification denotes an alkylphosphocholine compound with the molecular formula C21H46NO4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53EY29W7EC, chemically known as 3,5-dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-, hydroxide, inner salt, 4-oxide but generally known as miltefosine, which bears US NIH Compound Identifier 3599. European Medicines Agency schedules Miltefosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08969MIG.

UNSPSC 51101668 Miltefosine is a Commodity code that nominally describes a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows substantial mismatch between the code's narrow scope and the work being solicited. The opportunities posted against this code span a far broader range of pharmaceutical, medical supply, and pharmacy benefit management procurement — including naloxone and drug deactivation systems, medical and first aid supplies for emergency responders, generic pharmaceuticals and OTC products through cooperative purchasing, and therapeutic pharmacy initiative direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), city fire and rescue services (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The code does not reflect the actual scope of procurement activity being tagged to it, suggesting either broad misclassification by issuing bodies or use of this code as a catch-all for pharmaceutical and medical supply solicitations that do not fit cleanly into narrower commodity categories.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with recent opportunities posted between January and June 2026. Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000 and designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent SLBE bid discount not to exceed $10,000; MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local facilities; and the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs serving self-insured employee group health plans and state agencies.